Guidelines for the treatment of psoriatic arthritis with biologics

75 National Institute for Clinical Excellence. Improving outcomes for people with skin tumours including
melanoma In; 2010.
76 Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B
phototherapy: a British Photodermatology Group Workshop Report. The British journal of dermatology
2004;151(2):283‐97.
77 Marcil I, Stern RS. Squamous‐cell cancer of the skin in patients given PUVA and ciclosporin: nested
cohort crossover study. Lancet 2001;358(9287):1042‐5.
78 Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti‐tumor necrosis factor
alpha therapy for inflammatory arthritides. Arthritis and rheumatism 2001;44(12):2862‐9.
79 Stubgen JP. Tumor necrosis factor‐alpha antagonists and neuropathy. Muscle Nerve 2008;37(3):281‐
92.
80 Mahil SK, Andrews TC, Brierley C, Barker JN, Smith CH. Demyelination during tumour necrosis factor
antagonist therapy for psoriasis: a case report and review of the literature. J Dermatolog Treat 2012.
81 Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a
tumor necrosis factor antagonist. Annals of internal medicine 2003;138(10):807‐11.
82 Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent
heart failure in patients with rheumatoid arthritis? Arthritis and rheumatism 2008;58(3):667‐77.
83 Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti‐TNF therapies and pregnancy:
outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis
2011;70(5):823‐6.
84 Coates LC, Cawkwell LS, Ng NW, et al. Sustained response to long‐term biologics and switching in
psoriatic arthritis: results from real life experience. Ann Rheum Dis 2008;67(5):717‐9.
85 Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients
with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5‐year period. Ann Rheum Dis
2007;66(10):1393‐7.
86 Gomez‐Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an
observational study of 488 patients over a four‐year period. Arthritis research & therapy 2006;8(1):R29.
87 Mazzotta A, Esposito M, Costanzo A, Chimenti S. Efficacy and safety of etanercept in psoriasis after
switching from other treatments: an observational study. Am J Clin Dermatol 2009;10(5):319‐24.
88 Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis:
an open‐label study in 30 patients previously treated with other biologics. Journal of the American Academy of
Dermatology 2007;57(2):269‐75.
89 Spadaro A, Punzi L, Marchesoni A, et al. Switching from infliximab or etanercept to adalimumab in
resistant or intolerant patients with spondyloarthritis: a 4‐year study. Rheumatology (Oxford)
2010;49(6):1107‐11.
90 Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira)
restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept
(Enbrel): results from the STURE registry at Karolinska University Hospital. Scandinavian journal of
rheumatology 2005;34(5):353‐8.
25